GSK plc (LON:GSK) Given Consensus Recommendation of “Hold” by Brokerages

GSK plc (LON:GSK) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is GBX 2,048.57.

A number of brokerages have weighed in on GSK. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a report on Wednesday.

GSK Price Performance

Shares of GSK opened at GBX 1,846.50 on Friday. The firm has a market capitalization of £73.96 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The company’s fifty day moving average price is GBX 1,920.49 and its 200-day moving average price is GBX 1,983.22. GSK has a 1-year low of GBX 1,445 and a 1-year high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities research analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka bought 1,266 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Insiders have bought a total of 3,618 shares of company stock valued at $13,481,942 over the last quarter. 0.20% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.